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RECENT DEVELOPMENTS in the field of small-animal imaging have had a significant impact on
mouse tumor model research, which has proven to be
a powerful tool to improve our understanding of
human cancer. Mice tumor models can be imaged in
vivo employing optical fluorescent imaging techniques
using fluorescent proteins, dyes, or quantum dots.
Furthermore, antibodies labeled with near-infrared
(NIR) fluorescent probes provide an optimal tool for
studying tumor physiology, metastasis pattern, and
tumor response to drug treatments.1,2
Time-domain technology allows for whole-body
NIR fluorescence lifetime analysis, based on both the
specificity of fluorescence probes and the sensitivity of
their emission lifetime to environmental characteris-
tics. The tumor’s metabolic microenvironment (micro-
circulation, blood flow oxygen, tissue pH distribution,
bioenergic status) can vary significantly within a
tumor and between tumors of the same grading and
clinical staging.3 As a consequence, preliminary stud-
ies reported in the literature show that lifetime imag-
ing may be useful in investigating local environmental
changes caused by malignancy inside the body, thus
providing a tool for tumor localization and its spatial
functional status. Hassan and colleagues presented
preliminary results suggesting that trastuzumab conju-
gated to the chosen NIR fluorophore (Alexa Fluor
750) provides reasonable sensitivity of fluorescence
lifetime to some characteristics of the surrounding
medium, in particular, pH.4 In another study, the fluo-
rescence lifetime of a Cypate conjugate at the tumor
site was mapped, showing the spatial distribution of
lifetime related to its environment. The tumor showed
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Abstract
Rituximab is a chimeric monoclonal antibody directed against human CD20 antigen, which is expressed on B-cell lympho-
cytes and on the majority of B-cell lymphoid malignancies. Herein we report the conjugate of rituximab with the near-infrared
(NIR) fluorophore Cy5.5 (RI-Cy5.5) as a tool for in vitro, in vivo, and ex vivo NIR time-domain (TD) optical imaging. In
vitro, RI-Cy5.5 retained biologic activity and led to elevated cell-associated fluorescence on tumor cells. In vivo, TD optical
imaging analysis of RI-Cy5.5 injected into lymphoma-bearing mice revealed a slow tumor uptake and a specific long-lasting
persistence of the probe within the tumor. Biodistribution studies after intraperitoneal and endovenous administration were
undertaken to evaluate differences in the tumor uptake. RI-Cy5.5 concentration in the organs after intraperitoneal injection
was not as high as after endovenous injection. Ex vivo analysis of biologic tissues and organs by both TD optical imaging
and immunohistochemistry confirmed the probe distribution, as demonstrated by imaging experiment in vivo, showing that
RI-Cy5.5 selectively accumulated in the tumor tissue and major excretion organs. In summary, the study indicates that NIR
TD optical imaging is a powerful tool for rituximab-targeting investigation, furthering understanding of its administration
outcome in lymphoma treatment.
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a higher average lifetime when localized in the liver,
reflecting its altered physiopathology.5
In this study, we examined the conjugate of ritux-
imab with NIR fluorophore Cy5.5 (RI-Cy5.5) as a
tool for in vitro, in vivo, and ex vivo NIR imaging.
Rituximab is a chimeric monoclonal antibody
directed against human CD20 antigen, which is
expressed on B-cell lymphocytes and on the majori-
ty of B-cell lymphoid malignancies.6,7 It is composed
of two heavy chains of 451 amino acids and two
light chains of 213 amino acids. It has an approxi-
mate molecular weight of 145 kDa. Rituximab was
approved by the US Food and Drug Administration
in combination with chemotherapy for lymphoma8
and in combination with methotrexate for the treat-
ment of rheumatoid arthritis in patients who failed
to achieve adequate benefit from tumor necrosis fac-
tor α inhibitors.9
The conjugate RI-Cy5.5 led to elevated cell-
associated fluorescence on tumor cells. In vivo imag-
ing with a small-animal time-domain eXplore Optix*
imager allows the visualization of lymphoma
xenograft with RI-Cy5.5 administrated by both
endovenous and intraperitoneal routes. Biodistribution
and lifetime analysis are reported. 
Materials and Methods
Mouse Model of Lymphoma 
Female severe combined immunodeficiency (SCID)
mice (4–6 weeks of age) were purchased from Charles
River and maintained under pathogen-free condi-
tions. A similar xenograft model described by Macor
and colleagues was employed to investigate the in
vivo effects of Cy5.5 conjugates.10 Briefly, BJAB
human lymphoblastoid cells were expanded in vitro
and then implanted intraperitoneally (right flank, 2 ×
106/mouse) in SCID mice. Fifteen to 20 days after
implantation, mice that developed a solid mass were
treated intraperitoneally or endovenously with 50 µg
of RI-Cy5.5. Four lymphoma-bearing animals and
two wild-type mice were imaged for each administra-
tion route.
All experimental procedures were done in compli-
ance with the guidelines of European (86/609/EEC)
and Italian (D.L.116/92) laws and were approved by
the Italian Ministry of University and Research and
the Administration of the University Animal Facility.
Synthesis and In Vitro Characterization of
Rituximab Labeled with an NIR Probe
Conjugation of Dye to Antibody
The dye was the N-hydroxysuccinimide ester of cya-
nine 5.5 (Fluorolink Cy5.5 Monofunctional Dye 5-
pack, Amersham Biosciences). Rituximab was derived
from the residue of the first injection of antibody in
patients (Dr. Iannone, Hematology and BMT Unit,
Department of Oncology, University of Palermo,
Palermo, Italy).
Rituximab was dissolved at 1 mg/mL in phosphate
buffer. A freshly prepared solution of dye (0.05 mg/mL)
in sodium carbonate buffer (0.1 M), pH 9.3, was
added to the antibody solution (volume ratio 1:1). The
reaction was performed by gently shaking the tube at
room temperature for 1 hour. Labeled antibody was
separated from the excess, unconjugated dye by dialy-
sis against phosphate buffer (pH 7.4). Estimation of
the final dye to protein ratio was performed measuring
the absorbance of the solution at 678 nm and 280 nm.
Molar extinction coefficients of 250,000 M–1 cm–1 at
678 nm for the Cy5.5 dye and 170,000 M–1 cm–1 at
280 nm for the protein were used. Molar concentra-
tions of dye and protein were calculated, and the ratio
of these values represented the average number of dye
molecules coupled to each protein molecule. All sol-
vents and chemicals were purchased from Sigma-
Aldrich (Milan, Italy).
Immunofluorescence Analysis
Lymphoma cells were cultured in RPMI medium (Gibco,
Carlsbad, CA) supplemented with 10% fetal calf serum.
A total of 5 × 105 cells were incubated with the primary
antibody to CD20 rituximab or Monofunctional Dye 
5-pack conjugated rituximab at 5 µg/mL in phosphate
saline containing 1% bovine serum albumin for 1 hour
at 37˚C and then with the appropriate fluorescein
(FITC)-conjugated rabbit anti human IgG (Dako, A/S,
Denmark) for 1 hour at 37˚C in the dark. All of the anti-
bodies used were diluted in phosphate-buffered saline
containing 1% bovine serum albumin. After washing
with the same medium, the cells were fixed with 1%
paraformaldehyde (Sigma-Aldrich). 
Cell fluorescence was analyzed employing a
FACScalibur instrument (BD Biosciences, Milan, Italy)
equipped with an air-cooled 15 mW argon-ion laser oper-
ating at 488 nm. FITC green fluorescence was measured
at 530 ± 30 nm bandpass filter. Data were collected using
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linear amplification for forward and side scatter and log-
arithmic amplification for FL1. For each sample, 10,000
events were collected and analyzed using CellQuest soft-
ware (BD Biosciences, Franklin Lakes, NJ).
SDS-PAGE  
Rituximab (10 µg) and Monofunctional Dye 5-pack
conjugated rituximab (10 µg) were subjected to SDS-
PAGE according to the Laemmli method on a 4%
stacking–8% resolving gel under nonreducing condi-
tions in SDS buffer containing bromophenol blue.
Electrophoresis was performed for 30 minutes at 10 mA
gel -1 and then at 20 mA gel -1 until the dye front
reached the bottom of the gel. The gel was then ana-
lyzed with a small-animal time-domain eXplore Optix
imager to visualize the fluorescence intensity of
Monofunctional Dye 5-pack conjugated rituximab,
consecutively stained for 60 minutes with Brilliant
Blue R solution (Sigma-Aldrich), and finally destained
with a 10% acetic acid and 30% methanol solution.   
Mouse Preparation for Optical Imaging
Mice were anesthetized using zolazepam plus xylazine
(0.4 mL zolazepam 100% plus 0.25 mL xylazine 2%
dilute 1:5; 3.2 µL of the mixture/g body weight intra-
muscular), and the belly patch was shaved to avoid
laser scattering caused by hair. A blank image was
acquired before treating the animals, and then the
mice were injected intraperitoneally or endovenously
with 50 µg/mouse of rituximab chimeric monoclonal
antibody carrying Cy5.5.
In Vivo Time-Domain Optical Imaging
The small-animal time-domain eXplore Optix* pre-
clinical imager was used in this study. 
In all imaging experiments, a 670 nm pulsed laser
diode with a repetition frequency of 80 MHz and a
time resolution of 12 ps light pulse were used for exci-
tation. Fluorescence emission was collected at 700 nm
and detected through a fast photomultiplier tube and
a highly sensitive time-correlated single-photon count-
ing system. Two-dimensional scanning regions of
interest (ROIs) were selected, and laser power, integra-
tion time, and scan step were optimized according to
the emitted signal. The data were recorded as tempo-
ral point-spread functions, and the images were recon-
structed as fluorescence intensity and fluorescence life-
time. Prior to injecting the probe, mice were imaged to
obtain background images.
Ex Vivo Tissue Analysis
Two mice for both routes of administration were sac-
rificed by cervical dislocation to perform the ex vivo
analysis. Tissues of interest, such as tumor, liver, 
kidney, spleen, heart, lung, lymph nodes, and thigh
bones, were collected. The tissues were first washed
in phosphate-buffered saline and then analyzed with
the eXplore Optix*. 
Histopathologic and Immunohistochemical
Analysis
Following ex vivo analysis, tissue samples were fixed in
10% buffered formalin and embedded in paraffin. Four
micrometer thick sections were cut from paraffin blocks
for morphologic and immunohistochemical analysis.
Histopathologic evaluation of primary tumors and lym-
phomatous infiltrates in various tissues and organs was
carried out on sections stained with hematoxylin and
eosin. For immunohistochemistry, sections were
deparaffinized and rehydrated in water, and antigen
retrieval was performed by microwave oven treatment.
The CD20 antigen expression was tested by means of a
monoclonal antihuman CD20 antibody (clone L26,
Dako, Denmark) recognizing a different epitope from
that of rituximab and using the streptavidin-biotin-
peroxidase complex method according to standard pro-
cedures. Detection of injected rituximab in lymphoid
infiltrates and tissues was carried out by incubating
slides, which did not undergo microwave oven treat-
ment, with a secondary antihuman Fc antibody.
Immunostainings were revealed using 3-3'-iaminobenzi-
dine (DAB) as a chromogen and hematoxylin as nuclear
counterstaining. All slides were evaluated by an expert
pathologist under a Leica DM200 optical microscope
(Leica, Germany), and microphotographs were taken
using a Leica DC320 digital camera.
Data Processing 
The background signal intensity recorded with the
baseline image for each animal before the injection of
the probe was subtracted from each postcontrast
image. eXplore Optix* OptiView software (GE
Healthcare, United Kingdom) was used to estimate
fluorescence intensity and lifetime.11
Fluorescence Lifetime Analysis
The fluorescence lifetime analysis was based on a sin-
gle or two exponential fitting models applied to the
temporal point-spread function.12
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Fluorescence Intensity Analysis 
The intensity maps of acquired data were compared as
normalized counts working on multiple images.
Namely, for normalized counts, the photon counts
over the temporal point-spread function curves were
normalized with laser power and integration time,
whereas scan step remained constant. To perform the
comparison, an identical region of interest on each
image was positioned to encompass the area under
investigation. The resulting numerical data expressed
as normalized counts were analyzed after exporting to
Microsoft Excel.
Results 
In Vitro Characterization of RI-Cy5.5
The absorption and fluorescence emission spectra of
RI-Cy5.5 conjugate were similar to those of free
Cy5.5, suggesting that the fluorescence property of
Cy5.5 was not affected by conjugation to rituximab.
The molar ratio of rituximab to Cy5.5 was estimated
to be 3; thus, 50 µg (0.34 nmol) of rituximab labeled
with 1 nmol of Cy5.5 resulted. The yield of synthesis
was 46%. 
Protein separation by SDS-PAGE has shown that
Cy5.5 conjugation did not modify antibody molecular
weight (Figure 1A); its analysis by the time-domain
eXplore Optix preclinical imager also showed NIR
emission of RI-Cy5.5, but no free cyanine was detect-
ed in the sample (Figure 1B). Cy5.5 conjugation could
also interfere with the ability of the rituximab to bind
CD20, so, for this reason, Cy5.5-labeled rituximab
was compared with unlabeled rituximab. BJAB cells
were incubated with the antibodies, with FITC-labeled
secondary antibody and then analyzed by flow cytom-
etry; as evidenced in Figure 1C, labeled and unlabelled
rituximab analyzed by antihuman FITC secondary
antibody showed similar binding, indicating that the
conjugation procedure did not alter the affinity of the
antibody.
To demonstrate that the RI-Cy5.5 conjugate can
act as a specific ligand for the CD20 receptor, we test-
ed it on BJAB cells and other lymphomatous cell lines.
When these cells were incubated in the presence of RI-
Cy5.5 and secondary with FITC–antihuman IgG, the
majority of both receptor-associated fluorescence and
FITC-derived fluorescence colocalized at the plasma
membrane. Moreover, control human IgG1 was not
able to bind these cell lines (data not shown). These
results suggested that tumor selectivity was provided
by the monoclonal antibody specificity.
Time-Domain Fluorescence Imaging of
Lymphoma-Bearing Mice Treated with NIR
Fluorescent Dye RI-Cy5.5  
Previously, Macor and colleagues set up an in vivo
model of human CD20+ B-cell lymphoma in SCID
mice to test the ability of human neutralizing minian-
tibodies to enhance the therapeutic effect of rituximab.
To prove a specific binding of rituximab, several other
recombinant human or chimeric monoclonal antibod-
ies were used as a negative control in this and other
models of non-Hodgkin lymphoma. These antibodies
did not shown any antitumoral activity, indicating that
they are not able to bind tumor cells. 
Figure 1.  In vitro characterization of rituximab-Cy5.5. Rituximab
and rituximab-Cy5.5 (RI0Cy5.5) were separated by SDS-PAGE
and analyzed using Coomassie Brilliant Blue R (A) or the time-
domain eXplore Optix preclinical imager (B). Fluorescence-
activated cell sorter analysis was used to evaluate the ability of the
molecules to bind CD20, as described in Materials and Methods
(C). FITC = fluorescein.
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In this work, a similar model of lymphoma-bearing
mice was treated intraperitoneally or endovenously
(tail vein) with RI-Cy5.5. Fifty micrograms of ritux-
imab labeled with 1 nmol of Cy5.5 was injected10
based on the therapeutic efficacy of rituximab (maxi-
mal effect observed at 150 µg in mice) and the proto-
col followed in previous experiments (double injection
of 25  + 25 µg).
Intraperitoneal Injection 
After injection of RI-Cy5.5, lymphoma-bearing mice
were imaged every 30 minutes for the first  6 hours and
then every 24 hours for 10 days. Whole-body scans
showed the highest fluorescence signal in the region of
probe injection, whereas intensity decreased exponen-
tially and remained confined to a restricted area (Figure
2A). Comparing different animals injected intraperi-
toneally with equal volume and concentration of RI-
Cy5.5, a variability in fluorescence intensity progression
at the site of injection level was observed (Figure 2B). 
To optimize laser power and integration time
parameters, the probe injection regions were main-
tained outside the scanning area and the body was
divided into three regions: xenografted tumor, thorax,
and abdomen. The contrast between the tumor and
surrounding tissue increased slowly and was signifi-
cantly higher than precontrast from 24 hours until 10
days after injection (Figure 3A). The fluorescence life-
time of RI-Cy5.5 at the xenografted tumor site was
mapped, showing spatial distribution of lifetime in
relation to the environment. The lifetime range was
1.83 to 1.93 ns for the inner part of the tumor and
1.70 to 1.75 ns for the tissue surrounding the tumor
(see Figure 3A). Targeting of the probe into the inner
part of the tumor was estimated by following the flu-
orescence intensity of the ROIs, encompassing the
tumor tissue, and presenting a lifetime between 1.85
and 1.87 ns. The fluorescence emission reached its
maximum around 96 hours postinjection (Figure 3B).
The fluorescence intensity of the ROIs over time
was quantified as a measure of clearance from tissues
and organs. A time course for targeting and clearance
of the RI-Cy5.5 from lymph nodes was monitored
(Figure 3C).
Figure 2.  A, Whole-body scan of a lymphoma-
bearing mouse injected intraperitoneally with 
50 µg rituximab-Cy5.5 (corresponding to 1 nmol
Cy5.5) at the indicated time postinjection. The
site of probe injection showed the highest fluores-
cence signal and a lifetime of 1.40 to 1.42 ns,
which remained confined to a restricted area and
was detectable for up to 96 hours. B, A represen-
tation of the signal level decay describing the
clearance of rituximab-Cy5.5 from the site of
injection (the values indicate mean ± standard
error of measurement of three independent
experiments). NC = normalized count.
molecular-7-6  11/26/08  4:30 PM  Page 276
Time-Domain Optical Imaging Rituximab Cy5.5 277
Figure 3.  Intraperitoneal injection. Tumor and lymph node biodistribution of 50 µg rituximab-Cy5.5 (corresponding to 1 nmol Cy5.5) in 
lymphoma-bearing mice after intraperitoneal (i.p.) injection. A, Fluorescence emission in regions of interest encompassing the solid xenograft-
ed tumor was acquired at the indicated time postinjection and normalized. Fluorescence intensity and corresponding lifetime map are shown.
B, The graphs indicate the targeting of the probe to xenografted tumor after intraperitoneal injection and its comparison with the profile after
endovenous (e.v.) injection. The values indicate mean ± standard error of measurement of three independent experiments. C, Fluorescence
emission in regions of interest encompassing the thorax was acquired at different times postinjection and normalized. A representative mouse
is shown, with the corresponding profiles describing the targeting of the probe to lymph node areas. NC = normalized count.
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Lifetime values were 1.60 to 1.65 ns for the armpit
lymph nodes, 1.40 to 1.42 ns at the site of injection,
and 1.5 to 1.6 ns for the liver. 
Ex vivo evaluation of organs at 96 hours postinjec-
tion (Figure 4) clearly showed that the highest signal
of fluorescence emission was associated with tumor
tissue. RI-Cy5.5 was also found in the liver and the
kidneys, organs involved in the elimination of the
compound. 
Endovenous Injection
The total dose of RI-Cy5.5 (50 µg RI, 1 nmol
Cy5.5/mouse) was the same as that used for intraperi-
toneal administration.
Imaging was performed every 30 minutes for the
first 5 hours and then every 24 hours for 10 days
(Figure 5A). Following injection, RI-Cy5.5 was rapid-
ly taken up by the liver and gradually washed out.
Targeting of the probe to the tumor was evaluated as
described before; it was at maximum level after 48
hours postinjection and was slowly eliminated over
the following 8 days (Figure 5C). Fluorescence lifetime
was estimated, and values comparable to those
obtained after intraperitoneal injection were obtained
for the inner part of the tumor, its surrounding tissue,
and the lymph nodes. The liver presented a lifetime
between 1.5 and 1.6 ns. A time course for targeting
and clearance of the RI-Cy5.5 from lymph nodes was
monitored (Figure 5B).
Ex vivo evaluation of organs at 96 hours postinjec-
tion showed that the highest fluorescence intensity was
localized in the tumoral mass. The high fluorescence
emission was recorded in the liver and then in the kid-
neys, emphasizing that the compound is excreted
through these organs (see Figure 4).
Immunohistochemical Detection of Rituximab in
Primary Tumors
Primary tumors and organs from intraperitoneally and
endovenously treated mice and from untreated controls
were fixed following ex vivo imaging for immunohisto-
chemical analysis. At involved sites, lymphomatous cells
showed a strong membrane reactivity to anti-CD20
staining (Figure 6A). Consistently, rituximab binding
was detected in the context of lymphoid infiltrates in the
form of a membrane staining slightly diffusing to the
interstitium (Figure 6B). In primary tumors, rituximab
binding, highlighted by the secondary antihuman anti-
body, was localized mainly in the peripheral areas of the
tumor masses, often characterized by lytic changes and
necrosis (Figure 6, C–D, arrows). Besides lymphoma-
tous infiltrates, antihuman reactivity was also observed
in hepatic sinusoids and venules (Figure 6E, red
arrows), as well as in the glomerular capillaries and
arterioles of the kidney (Figure 6F, red arrows). In both
sites, scattered monocytoid cells also showed cytoplas-
mic reactivity to antihuman antibody (Figure 6, E–F,
black arrows). G to I in Figure 6 refer to the controls. 
Figure 4. Ex vivo analysis. A, Ex vivo profile of 50 µg rituximab-Cy5.5 (corresponding to 1 nmol Cy5.5) dis-
tribution after endovenous (e.v.) (black bars) and intraperitoneal (i.p.) (white bars) injection in lymphoma-
bearing mice. Data represent mean values ± range (n = 2). B, Ex vivo images of organs at 96 hours after
endovenous and intraperitoneal injection. Imaging of the organs was performed immediately after sacrifice:
laser power and integration time were optimized while keeping scan step constant to compare fluorescence
intensities after normalization. NC = normalized count.
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Figure 5.  Intravenous injection. Biodistribution of 50 µg pf rituximab-Cy5.5 (corresponding to 1 nmol Cy5.5) in lymphoma-bearing mice
after endovenous (e.v.) injection. A, Whole-body fluorescence intensity was acquired at the indicated time postinjection and normalized. B,
Fluorescence emission in regions of interest encompassing the thorax were acquired at different times postinjection and normalized. A rep-
resentative mouse is shown, with the corresponding profiles describing the targeting of the probe to lymph node areas. C, Fluorescence emis-
sion in regions of interest encompassing the solid xenografted tumor were acquired at the indicated time postinjection and normalized.
Fluorescence intensity and corresponding lifetime map are shown. The graphs indicate the targeting of the probe to xenografted tumor after
endovenous injection. The values indicate mean ± standard error of measurement of three independent experiments. NC = normalized count.
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Overall, no differences were found between sam-
ples from intraperitoneally and endovenously injected
mice in regard to the immunohistochemical detection
of rituximab.
Discussion
Rituximab is a chimeric monoclonal anti-CD20 anti-
body used in clinical settings for the treatment of some
non-Hodgkin lymphomas6,7 and some autoimmune
conditions.9 It has already been characterized in sever-
al animal models for its functional activity,13 but a
complete biodistribution profile of this drug has never
been obtained.14,15 In the present work, time-domain
optical imaging allowed us to carry out longitudinal
animal studies evaluating the biodistribution of a cya-
nine 5.5–labeled rituximab over time in the same ani-
mal for a prolonged time (7–10 days) until its com-
plete elimination. 
The in vivo and ex vivo time-domain analysis of
lymphoma-bearing mice injected with equal amounts
of RI-Cy5.5 showed some differences in biodistribu-
tion after intraperitoneal and endovenous injections.
In general, fluorescence intensity in the organs after
intraperitoneal injection was not as high as after
endovenous injection. In fact, after intraperitoneal
treatment, the probe must be absorbed by the peri-
toneal cavity before reaching the bloodstream, where-
as with the endovenous route of administration, the
compound is injected into the bloodstream directly.
RI-Cy5.5 reached the tumoral region faster and with a
higher concentration by endovenous administration
compared with intraperitoneal treatment. The maxi-
mum fluorescence emissions were observed 72 hours
after endovenous injection and 96 hours after
intraperitoneal injection. The peculiar difference in the
rate of tumor uptake of RI-Cy5.5 suggested an advan-
tage in using the intraperitoneal route of administra-
tion instead of the endovenous one, when there is a
need to induce therapeutical effect mimicking slow-
release delivery. 
Ex vivo analysis confirmed the probe distribution
and showed that RI-Cy5.5 is selectively accumulated
in the tumor tissue and major excretion organs, as
observed in the in vivo experiments.
The lifetime of RI-Cy5.5 changed significantly
when distributed in the liver, tumor, lymph nodes and
Figure 6.  Immunohistochemical detection of rituximab in primary tumors. A, Primary tumors and lymphomatous infiltrates are composed by
medium to large atypical lymphoid cells with a diffuse growth pattern and strong membrane CD20 expression. B, Immunohistochemistry per-
formed using a secondary antihuman Fc antibody highlighted the presence of rituximab in the neoplastic aggregates, in the form of a mem-
brane staining diffusing to the interstitium. C–D, Rituximab is mostly detected at the periphery of the tumor masses where a high degree of
cell lysis is observed. E–F, Binding of secondary antihuman Fc is observed in the hepatic sinusoids and central venules (E, red arrows), as well
as in the glomerular capillaries and arterioles in the kidney (F, red arrow), suggesting the presence of rituximab in these sites. Reactivity to anti-
human Fc is also observed in the cytoplasm of scattered monocytoid cells (black arrows). G–H, Negative controls performed on the same sam-
ples shown in E and F by incubating slides with an irrelevant (antimouse) secondary antibody. A–H, Immunohistochemistry performed by the
streptavidin-biotin-peroxidase complex method using DAB (yellow-brown signal) chromogen and hematoxylin nuclear counterstaining.
Original magnifications: A and C–H, ×200; B and F (inset), ×400. I, Antihuman Fc staining of an untreated tumor. Bars = 100 µm.
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bladder. Moreover, the large differences in the life-
time of RI-Cy5.5, food, and exogenous fluorophore,
respectively, minimized spectral overlap. This
allowed a lifetime gating analysis to be performed,
namely, to directly correlate the fluorescence emis-
sion to specific lifetime range values to select only RI-
Cy5.5 and eliminate background signal. This facili-
tated imaging of the distribution of the RI-Cy5.5 and
correlating its spatial distribution with the microen-
vironment of the tumor. Namely, lifetime gating
analysis allowed us to distinguish the two different
microenvironments inside the tumor mass, showing,
with both intraperitoneal and endovenous injection,
a lower lifetime in the margin and a higher lifetime in
the center of the xenografted tumor. Our finding
regarding NIR fluorescent Cy5.5 lifetime analysis in
a tumor model agrees with previous results on carbo-
cyanines, indicating that the lifetime analysis
approach is an effective medium in providing infor-
mation on tissue microenviroment. Previous studies
demonstrated that NIR fluorescent Cypate conju-
gates can map the spatial distribution of lifetime in
relation to tumor environment.5
Time-domain optical imaging technology allowed
us to monitor probe absorption at  the intraperitoneal
injection site. The probe was detectable at the injection
site for 96 hours. Comparing different animals inject-
ed intraperitoneally, we observed a variability in fluo-
rescence intensity progression at the injection level. We
supposed that such a variability was inherent with the
administration route. In fact, intraperitoneal injections
deliver RI-Cy5.5 to the peritoneal cavity, and the
amount that distributes systematically depends on the
rate and the amount of compound traveling from the
peritoneal cavity into the bloodstream. Moreover,
fluid distribution in the peritoneal cavity depends on
the complex recesses that characterize it. Therefore,
differences persist between animals in the absorption
capacity from the peritoneal cavity, as observed. These
findings are consistent with previously reported results
obtained with small-animal positron emission tomog-
raphy,16 thus confirming that the sample volumes are
of concern for intraperitoneal injection and that 
injecting samples of equal volumes leads to more
reproducible results. Although further experiments are
required to quantify the best conditions (in terms of
volume and concentration of Cy5.5-labeled antibod-
ies) for intraperitoneal injections, we assessed the 
ability of time-domain optical imaging technology to
optimize experimental protocols relative to this
administration route.
The monitoring of other districts than the tumor
(eg, lymph nodes) confirms the possibility of applying
this technology not only to study the primary tumor
region but also to evaluate the distribution of drugs in
different “metastatic” regions. After injection in the
peritoneum, the biomarker is distributed throughout
the whole organism through blood circulation and
localized in lymph node regions within 48 hours, and
it is possible to detect the compound up to 96 hours
after treatment. The same peaks of fluorescence inten-
sity are detectable in the mouse treated endovenously
with the tested compound, but, as shown in the respec-
tive images, in this case, the signal in the lymph nodes
was stronger. 
Immunohistochemical analyses were performed to
confirm data obtained using time-domain optical
imaging. The immunohistochemical detection of ritux-
imab has not shown differences between intraperi-
toneally and endovenously injected mice in the excised
organs at 96 hours postinjection, generally confirming
data collected from ex vivo analysis. This technique
appears to be less sensitive than optical imaging and
permitted us to visualize Fc portions of rituximab in
primary tumors, but lymphomatous infiltrates or rit-
uximab was also observed in hepatic sinusoids and
venules, as well as in the glomerular capillaries and
arterioles of the kidney.
Conclusion
We used the eXplore Optix* system, a time-domain
optical imaging technology, to demonstrate how ritux-
imab, a chimeric monoclonal antibody directed
against human CD20 antigen, maintained its function-
al characteristics after being conjugated to the fluo-
rophore cyanine 5.5 and injected in mice bearing a
human lymphoma and how rituximab is specifically
uptaken by the tumor and the metastatic regions. Ex
vivo analyses were performed to confirm the organs’
fluorescence emissions recorded in vivo. Moreover, we
studied the differences in biodistribution between two
routes of administration, the intraperitoneal and the
endovenous one.
Our findings indicated that lifetime of RI-Cy5.5 is
a parameter sufficiently sensitive to discriminate
between the exogenous signal of RI-Cy5.5 and auto-
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fluorescence and to monitor changes in the tumor tis-
sue microenvironment. Finally, we were able to assess
that this noninvasive technology allows us to conduct
longitudinal studies in the same animal and that it is
possible to obtain accurate recovery of fluorophore
distribution. 
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